SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,281. The last known price of Bitcoin is 71,086.72423286 USD and is down -3.89 over the last 24 hours. It is currently trading on 12779 active market(s) with $28,515,435,687.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and break below key support levels are dominating discussion, with traders pointing to leveraged-long liquidations and broader risk-off pressure across crypto and tech as possible contributors. The community is split between warnings of further downside and calls to buy an oversold dip or watch for support.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas reiterated that topline results from its Phase 3 REGAL trial of GPS in AML are expected in November after the trial reached its required event milestone, drawing attention to the pending binary readout. Traders are broadly excited about the prospect of positive data and a short squeeze, while speculation about a leak or buyout remains unconfirmed and skeptics stress that results have not been released and the trial outcome is uncertain.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage disrupted Outlook, Teams, Copilot and other services, prompting complaints about work interruptions and concern that the prolonged disruption could damage trust or pressure the stock. Some traders speculated about a cyberattack, but the cause was not confirmed, and others questioned why shares held relatively steady.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs decision to remove Strategy from its indexes is fueling concerns about passive fund selling, while Bitcoins decline adds pressure to the stock. Traders debate whether the potential outflows are already priced in and whether the exclusion will materially weaken Strategys Bitcoin-linked financing model.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.03439229 USD and is down -2.16 over the last 24 hours. It is currently trading on 1895 active market(s) with $1,786,076,895.36 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs sharp decline toward the $1 support level amid a broader crypto selloff is dominating discussion, with traders pointing to Bitcoin weakness, inflation and rate concerns, and liquidations. Bears warn of further downside and question Ripples ability to provide catalysts, while some holders view the drop as a buying opportunity and continue accumulating.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,962,604.07029401. The last known price of Zcash is 956.58767703 USD and is down -2.92 over the last 24 hours. It is currently trading on 670 active market(s) with $828,877,374.43 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp pullback after a major rally is dominating discussion, with traders debating whether it is a broader crypto-market correction and liquidation flush or a deeper breakdown. Some call the selloff an oversold buying opportunity, while bears point to lost support and continued selling.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs resignation and Colette Kresss interim appointment have rattled NVDA shares, with traders also debating potential China chip-export scrutiny and the companys reliance on Huangs leadership. The community is split between buying the selloff on confidence in Nvidias AI business and avoiding the stock amid leadership and regulatory uncertainty.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned prostate-cancer BLA filing has been pushed to mid-2027 amid FDA discussions and assay refinement, prompting a sharp selloff and criticism of managements communication and credibility. Some traders see the delay as a manufacturing and regulatory hurdle rather than a problem with the clinical data, while others remain concerned about execution and the longer wait.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Weakness in Ethereum and broader crypto-linked stocks is weighing on BitMine, while traders also criticize its underperformance and question managements spending, transparency, and buybacks. Some see the stocks discount to its crypto holdings as a buying opportunity, but bearish posts argue falling ETH prices can overwhelm any support from repurchases.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is under pressure as Bitcoin and broader crypto markets sell off, with traders highlighting COINs repeated new lows and weak performance even when Bitcoin stabilizes. Bearish calls dominate, though some see the decline as oversold and are buying the dip.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Brief Healthcare: PolyPeptide: Strategic Review Is Real, But the Setup Isn’t Clean and more

In this briefing: PolyPeptide: Strategic Review Is Real, But the Setup Isn’t Clean Aequitas: Integris Medtech Ltd Pre-IPO: Medtech Platform with Strong Growth but Elevated Leverage Tetratherix Limited - Commercialising the Platform Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 1. PolyPeptide: Strategic Review Is Real, But the Setup Isn’t Clean PolyPeptide is in a credible strategic review process, but at CHF37.25 the market already prices a 58.3% deal probability, leaving limited upside relative to downside risk in a break scenario. While a full re-rating implies valuation above CHF 50, sponsor return constraints anchor a realistic takeout in the low-to-mid 40s, supported by LBO analysis and peer multiple comparisons. The controlling shareholder structure introduces a third outcome where minorities may not receive a full premium, meaning “a deal” does not necessarily translate into immediate value crystallisation for investors. 2. Aequitas: Integris Medtech Ltd Pre-IPO: Medtech Platform with Strong Growth but Elevated Leverage Integris Medtech Limited (1234518D IN) (IML) plans to raise around US$340m in its upcoming IPO.

Brief Healthcare: Tetratherix Limited - Commercialising the Platform and more

In this briefing: Tetratherix Limited - Commercialising the Platform Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 Sirius (靖因生物) Pre-IPO: Pipeline Prioritization and Competitor Updates TransThera Placement (2617 HK): Tinengotinib Alone Can’t Signal Any Major Upheaval of Fortunes 1. Tetratherix Limited - Commercialising the Platform Tetratherix Limited (ASX:TTX) is an Australian biomedical company commercialising a proprietary polymer platform, Tetramatrix, across four franchises: bone regeneration, tissue spacing, tissue healing and precision medicine. Tetramatrix is a novel fully synthetic, water-based injectable polymer that transitions from a liquid to a solid matrix/scaffold when it enters the human body (at 37°C). As the product mimics natural tissue, it offers potential advantages versus existing animal-derived solutions that are prone to immune responses like inflammation. 2. Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Solara is a pure-play Active Pharmaceutical Ingredients (API) manufacturer emerging from a significant operational and financial reset, showing early signs of a turnaround with improved profitability and cash flows in the most recent fiscal year.

Brief Growth Ideas: Primer: Page Industries (PAG IN) - Apr 2026 and more

In this briefing: Primer: Page Industries (PAG IN) - Apr 2026 Primer: Arvind Fashions (ARVINDFA IN) - Apr 2026 Primer: Vedant Fashions (MANYAVAR IN) - Apr 2026 Aequitas: Rentmojo Ltd Pre-IPO Tearsheet Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 1. Primer: Page Industries (PAG IN) - Apr 2026 Market Leader with a Strong Brand Moat: Page Industries is the dominant player in the Indian premium innerwear and athleisure market, primarily through its long-term, exclusive license for the Jockey brand, which has been extended until 2040. This strong brand recognition and perceived quality command premium pricing and foster high consumer loyalty. Extensive and Evolving Distribution Network: The company possesses a formidable pan-India distribution network, including over 1,450 exclusive brand outlets (EBOs) and more than 125,000 retail touchpoints. Continuous expansion into Tier-2 and Tier-3 cities, coupled with a growing e-commerce presence, provides a robust platform for future growth.

Brief Equities Bottom-Up: Primer: Page Industries (PAG IN) - Apr 2026 and more

In this briefing: Primer: Page Industries (PAG IN) - Apr 2026 Primer: Arvind Fashions (ARVINDFA IN) - Apr 2026 Primer: Vedant Fashions (MANYAVAR IN) - Apr 2026 Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Sunwoda Electronic Co Ltd A (300207 CH) - Apr 2026 1. Primer: Page Industries (PAG IN) - Apr 2026 Market Leader with a Strong Brand Moat: Page Industries is the dominant player in the Indian premium innerwear and athleisure market, primarily through its long-term, exclusive license for the Jockey brand, which has been extended until 2040. This strong brand recognition and perceived quality command premium pricing and foster high consumer loyalty. Extensive and Evolving Distribution Network: The company possesses a formidable pan-India distribution network, including over 1,450 exclusive brand outlets (EBOs) and more than 125,000 retail touchpoints. Continuous expansion into Tier-2 and Tier-3 cities, coupled with a growing e-commerce presence, provides a robust platform for future growth.

Brief Equities Bottom-Up: Primer: Arvind Fashions (ARVINDFA IN) - Apr 2026 and more

In this briefing: Primer: Arvind Fashions (ARVINDFA IN) - Apr 2026 Primer: Vedant Fashions (MANYAVAR IN) - Apr 2026 Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Sunwoda Electronic Co Ltd A (300207 CH) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 1. Primer: Arvind Fashions (ARVINDFA IN) - Apr 2026 Arvind Fashions holds a strong position in India's apparel market through a focused portfolio of high-recognition, premium, and bridge-to-luxury brands, most notably the licensed brand U.S. Polo Assn., which is a significant revenue driver. The company is pursuing a clear growth strategy centered on expanding its retail footprint via an asset-light franchise model, enhancing its omnichannel capabilities, and growing its direct-to-consumer (D2C) business to improve margins and customer engagement. After a period of portfolio rationalization and financial volatility, the company has shown signs of a turnaround with improving profitability metrics and a strengthened balance sheet, although it faces intense competition and risks associated with licensed brand agreements.

Brief Growth Ideas: Primer: Arvind Fashions (ARVINDFA IN) - Apr 2026 and more

In this briefing: Primer: Arvind Fashions (ARVINDFA IN) - Apr 2026 Primer: Vedant Fashions (MANYAVAR IN) - Apr 2026 Aequitas: Rentmojo Ltd Pre-IPO Tearsheet Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Sunwoda Electronic Co Ltd A (300207 CH) - Apr 2026 1. Primer: Arvind Fashions (ARVINDFA IN) - Apr 2026 Arvind Fashions holds a strong position in India's apparel market through a focused portfolio of high-recognition, premium, and bridge-to-luxury brands, most notably the licensed brand U.S. Polo Assn., which is a significant revenue driver. The company is pursuing a clear growth strategy centered on expanding its retail footprint via an asset-light franchise model, enhancing its omnichannel capabilities, and growing its direct-to-consumer (D2C) business to improve margins and customer engagement. After a period of portfolio rationalization and financial volatility, the company has shown signs of a turnaround with improving profitability metrics and a strengthened balance sheet, although it faces intense competition and risks associated with licensed brand agreements.

Brief Growth Ideas: Aequitas: Rentmojo Ltd Pre-IPO Tearsheet and more

In this briefing: Aequitas: Rentmojo Ltd Pre-IPO Tearsheet Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Sunwoda Electronic Co Ltd A (300207 CH) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 X-Energy Inc. (XE): Amazon Backed Advanced Nuclear Reactor Tech Company Sets Terms for IPO 1. Aequitas: Rentmojo Ltd Pre-IPO Tearsheet Rentmojo Ltd (RMJL IN) s looking to raise about US$126m in its upcoming India IPO. The deal will be run by Axis, IIFL and Motilal Oswal. Rentmojo operates a technology-driven, full-stack direct-to-consumer online rental and subscription platform for furniture and appliances in India, spanning across category management, designing, procurement, refurbishment, servicing, reverse logistics and multi-cycle redeployment. According to Redseer, it was the largest home furniture and appliances online rental and subscription platform(based on live subscribers) as of FY25 and Sep 30, 2025, and subscription revenue(during FY25). 2. Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Solara is a pure-play Active Pharmaceutical Ingredients (API) manufacturer emerging from a significant operational and financial reset, showing early signs of a turnaround with improved profitability and cash flows in the most recent fiscal year.

Brief India: Aequitas: Rentmojo Ltd Pre-IPO Tearsheet and more

In this briefing: Aequitas: Rentmojo Ltd Pre-IPO Tearsheet Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 Primer: Home First Finance (HOMEFIRS IN) - Apr 2026 HSIE Results Daily: ICICI Prudential Life Insurance Company 1. Aequitas: Rentmojo Ltd Pre-IPO Tearsheet Rentmojo Ltd (RMJL IN) s looking to raise about US$126m in its upcoming India IPO. The deal will be run by Axis, IIFL and Motilal Oswal. Rentmojo operates a technology-driven, full-stack direct-to-consumer online rental and subscription platform for furniture and appliances in India, spanning across category management, designing, procurement, refurbishment, servicing, reverse logistics and multi-cycle redeployment. According to Redseer, it was the largest home furniture and appliances online rental and subscription platform(based on live subscribers) as of FY25 and Sep 30, 2025, and subscription revenue(during FY25). 2. Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Solara is a pure-play Active Pharmaceutical Ingredients (API) manufacturer emerging from a significant operational and financial reset, showing early signs of a turnaround with improved profitability and cash flows in the most recent fiscal year.

Brief Equities Bottom-Up: Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 and more

In this briefing: Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Sunwoda Electronic Co Ltd A (300207 CH) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 Sony Financial Group (8729) - Cheap Vs Peers and Growing Out of Its ROE Hole Primer: Aspial Corp Ltd (ASP SP) - Apr 2026 1. Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Solara is a pure-play Active Pharmaceutical Ingredients (API) manufacturer emerging from a significant operational and financial reset, showing early signs of a turnaround with improved profitability and cash flows in the most recent fiscal year. The company holds a strong position in several key products, including being a global leader in Ibuprofen, and benefits from a strong regulatory track record with approvals from major authorities like the US FDA and EDQM, which is critical for serving highly regulated markets. High operational gearing, significant historical earnings volatility, and intense competition in the generic API space present considerable risks, but the company's strategic shift towards higher-value products and improving financial health offer potential upside.

Brief India: Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 and more

In this briefing: Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 Primer: Home First Finance (HOMEFIRS IN) - Apr 2026 HSIE Results Daily: ICICI Prudential Life Insurance Company Pharmaceuticals: IPM: 11% growth in Mar-26, 10% in FY26 1. Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Solara is a pure-play Active Pharmaceutical Ingredients (API) manufacturer emerging from a significant operational and financial reset, showing early signs of a turnaround with improved profitability and cash flows in the most recent fiscal year. The company holds a strong position in several key products, including being a global leader in Ibuprofen, and benefits from a strong regulatory track record with approvals from major authorities like the US FDA and EDQM, which is critical for serving highly regulated markets. High operational gearing, significant historical earnings volatility, and intense competition in the generic API space present considerable risks, but the company's strategic shift towards higher-value products and improving financial health offer potential upside.

Solara Active Pharma Sciences Ltd. engages in the manufacture and development of active pharmaceutical ingredient. Its products include Albendazole, aprepitant, artesunate, brivaracetam, bumetanide, buspiron, cetirizine dihydrochloride, chlorpromazine, cinacalcet hydrochloride, citicoline sodium, colchicine, colesevelam, colestipol, cycloserine, dipyridamole, disulfiram, dolutegravir, edaravone, efinaconazole, ethacrynic acid, etomidate, felbamate, flecainide acetate, flucytosine, gabapentin, hydralazine, ibuprofen, imiquimod, indapamide, lanthanum carbonate octahydrate,levetiracetam, lurasidone, mebendazole, mefenamic acid, mesalamine, mesna, methohexital, methoxsalen, mirabegron, mycophenolate mofetil, naproxen base, nizatidine, obeticholic acid, alanzapine, patiromer sorbitex calcium, pentoxifyline, pitavastatin calcium, posaconazole, praziquantel, ranitidine, rebamipide, rifaximin, rotigotine, safinamide, sapropterin, sevelamer carbonate, succinylcholine, sucroferric oxyhydroxide, sugammadex, tioconazole, tranexamic acid and zileuton. The company was founded on February 23, 2017 and is headquartered in Chennai, India.

Solara Active Pharma Sciences Ltd.

Solara Stock In Pause Mode Before Next Move? SEBI RA Vijay Gupta Sees Healthy Setup

Equity

Neutral Sentiment

Solara Active Pharma shares have rallied 25% in the last one month. According to Vijay Kumar Gupta, a SEBI-registered analyst, the stock is now consolidating near a critical resistance zone after a decisive breakout.&nbsp;Its momentum looks healthy, supported by solid volumes and improving fundamentals, he added.&nbsp;On the technical charts, it is trading above Ichimoku cloud with a bullish bias. The price action is hovering in the Fair Value Gap zone, yet to clear its upper resistance.&nbsp;Gupta also noted that its Commodity Channel Index (CCI) stands near 98, indicating moderate bullish momentum without overextension.&nbsp;&nbsp;TTM Squeeze (a technical indicator that identifies periods of low volatility) shows fading histogram bars, indicating that the stock may experience a possible pause before a fresh move. Additionally, the volume consolidation suggests healthy digestion of gains.<stembedurl>https://stocktwits.com/VijayGuptaAdvisory/message/621871688</stembedurl>Fundamentally, Solara is one of India’s leading API manufacturers, focusing on chronic therapy segments like pain management and inflammation.&nbsp;Recent performance has been boosted by operational turnaround and restructuring efforts following its merger phase. It reported a 15% revenue growth in the March quarter, which also saw its profits tripling to ₹41 crore. Gross margins have expanded significantly due to better product mix. Going ahead, its debt reduction and working capital efficiency remain key positives.&nbsp;Gupta also noted that the management commentary hinted at stronger export orders and improved utilization in FY26.&nbsp;What’s Driving The Sentiment?According to Gupta, investor interest is returning in niche pharma plays, driven by financial deleveraging and margin expansion. Additionally, the global focus on API de-risking by clients is benefiting Indian manufacturers.&nbsp;However, data on Stocktwits shows that retail sentiment has been ‘bearish’ on this counter for a few weeks.&nbsp;<figure class="image"><img style="aspect-ratio:808/111;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_23_111838_png_d20ae7d100.webp" alt="Screenshot 2025-07-23 111838.png" width="808" height="111"><figcaption>Solara sentiment and message volume on July 23 as of 11:20 am IST. | source: Stocktwits</figcaption></figure>Solara shares have declined 4% year-to-date (YTD).For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration showing a mix of various tablets and pharmaceutical products, primarily manufactured by U.S. pharmaceutical companies. (Photo by Artur Widak/NurPhoto via Getty Images)

 Solara Pharma has gained 25% in a month and is now consolidating near a key resistance zone.

Current Price	710.35
Prev Close	680.00
Open	676.20
Dividend Yield	0.00%
50-Day Moving Average	680.16
Beta	N/A
Avg. Volume	528,691.00
PE Ratio	89.99

52-Week High	774.00
52-Week Low	422.00
Market Capitalization	32.08B
EPS (Annual)	-1.68
Price to Book	2.27
Revenue Per Employee	4.38M

Feed

News

Sentiment

Fundamentals

Info

SOLARA.NSE Fundamentals